Lipid-lowering drugs and serum liver enzymes: The effects of body weight and baseline enzyme levels

Fundamental and Clinical Pharmacology

Volumn 17, Issue 4, 2003, Pages 491-494

  Kiortsis, Dimitrios N ^a   Nikas, Spyridon ^a   Hatzidimou, Katerina ^a   Tsianos, Epaminondas ^a   Elisaf, Moses S ^a  

^a UNIVERSITY OF IOANNINA   (Greece)

Author keywords

Fibrates; Lipid lowering drugs; Liver enzymes; Obesity; Statins

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTILIPEMIC AGENT; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; ASPARTATE AMINOTRANSFERASE; ATORVASTATIN; CIPROFIBRATE; CREATINE KINASE; FENOFIBRATE; FIBRIC ACID DERIVATIVE; FIBRINOGEN; FLUINDOSTATIN; GAMMA GLUTAMYLTRANSFERASE; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPOPROTEIN A; LIVER ENZYME; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; BODY MASS; BODY WEIGHT; CONTROLLED STUDY; DRUG SAFETY; ENZYME BLOOD LEVEL; FEMALE; FOLLOW UP; HUMAN; HYPERLIPIDEMIA; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; OBESITY; PRIORITY JOURNAL;

ADULT; AGED; ANTILIPEMIC AGENTS; BODY MASS INDEX; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIVER; MALE; MIDDLE AGED;

EID: 0042670040     PISSN: 07673981     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1472-8206.2003.00176.x     Document Type: Article

References (8)

1. Frick M.H., Elo O., Haapa K. et al. Helsinki Heart Study: primary prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors and incidence of coronary heart disease. N. Engl. J. Med. (1987) 317 1237-1245.
2. Shepherd J., Cobbe S.M., Ford I. et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N. Engl. J. Med. (1995) 333 1301-1307.
3. Staels B., Dallongeville J., Auwerx J., Schoonjans K., Leitersdorf E., Fruchart J.C. Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation (1998) 98 2088-2093.
4. Sheth S.G., Gordon F.D., Chopra S. Nonalcoholic steatohepatitis. Ann. Intern. Med. (1997) 126 137-145.
5. Bellentani S., Saccoccio G., Masutti F. et al. Prevalence of and risk factors for hepatic steatosis in northern Italy. Ann. Intern. Med. (2000) 132 112-117.
6. Kiortsis D.N., Millionis H., Bairaktari E., Elisaf M. Efficacy of combination of atorvastatin and micronised fenofibrate in the treatment of severe mixed hyperlipidemia. Eur. J. Clin. Pharmacol. (2000) 56 631-635.
7. Marchesini G., Brizi M., Morselli-Labate A.M. et al. Association of nonalcoholic fatty liver disease with insulin resistance. Am. J. Med. (1999) 107 450-455.
8. Maron D.J., Fazio S., Linton M.F. Current perspective on statins. Circulation (2000) 101 207-213.